Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (BC).
Saved in:
| Title: | Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (BC). |
|---|---|
| Authors: | Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., Shparyk, Y., Thummala, A. R., Voytko, N. L., Breazna, A., Kim, S. T., Randolph, S., Slamon, D. J. |
| Source: | Cancer Research. Dec2012 Meeting Abstracts, Vol. 72 Issue 24a, p2171-2171. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
